Qiagen N.v. · NYSE:QGEN
Qiagen — Kepler Cheuvreux 18th German Corporate Conference, January 2019
22 slides from Qiagen's conference presentation, Jan 21, 2019
Slide 1: QIAGEN: Delivering solid growth and strengthening Sample to Insight portfolio
QIAGEN: Delivering solid growth and strengthening Sample to Insight portfolio Roland Sackers Chief Financial Officer Kepler Cheuvreux 18th German Corporate Conference, January 2019 Sample to Insight Kepler Cheuvreux German Corporate Conference, January 2019 1
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended
Slide 3: The building blocks of life: customers rely on QIAGEN for DNA and RNA molecular testing
THE BUILDING BLOCKS OF LIFE: CUSTOMERS RELY ON QIAGEN FOR DNA AND RNA MOLECULAR TESTING SOLUTIONS Sample Assay Bioinformatics technologies technologies Automation systems Sample to Insight QIAGEN: World leader in molecular testing solutions that advance science and improve outcomes for patients Samp
Slide 4: Addressing the world's most pressing challenges
ADDRESSING THE WORLD’S MOST PRESSING CHALLENGES Academia How can we achieve scientific breakthroughs even faster? Pharma How can we develop better and safer drugs? Applied Testing How can we improve public safety? Molecular Diagnostics How can we further improve outcomes for patients? Expanding rang
Slide 5: A most trusted brand found in virtually every lab worldwide
QIAGEN customer classes Product portfolio Global presence 9M 2018 net sales (% of total QIAGEN sales) 9M 2018 net sales (% of total QIAGEN sales) 9M 2018 net sales (% of total QIAGEN sales) Molecular Academia Diagnostics Americas Europe / ~22% Middle East / Africa ~32% ~49% Life Sciences ~12% ~88% ~
Slide 6: Nine-month 2018 achievements: delivering on targets
Levers Nine-month 2018 achievements Delivering on targets Sales ◼ Applying novel approaches to customer engagement ◼ Focusing portfolio (e.g. China strategy and veterinary assays divestment) Emerging disruptive portfolio ◼ QuantiFERON-TB: ~20% CER growth, new DiaSorin and Hamilton collaborations Sam
Slide 7: Life Sciences customer class
Portfolio strength Life Sciences customer class Academia ~$4 billion addressable market ◼ 12-month run rate of ~$750 million (as of Q3 2018) ~4% CER ◼ Recognized innovator supporting breakthrough science Pharma market growth ◼ Ability to translate innovations into commercial products Applied Testing
Slide 8: Advances in automated sample processing: QIAcube Connect
Portfolio strength Case study: Advances in automated sample processing QIAcube Connect ◼ QIAcube Connect: Next-generation automation for sample processing Enables labs to process increasingly complex samples Builds on installed base of >8,000 first generation QIAcubes ◼ Wide application range in
Slide 9: Reinventing digital PCR
Portfolio strength Case study: Reinventing digital PCR New QIAGEN digital PCR platform ◼ Acquisition of digital PCR technology from Formulatrix Fully integrated platform New instrument range in late-stage development by QIAGEN ◼ Partitioning, thermal cycling Commercialization planned for 2020 an
Slide 10: Industry-leading portfolio for any sequencer: Universal NGS solutions
Portfolio strength Case study: Industry-leading portfolio for any sequencer Universal NGS (UNGS) solutions ◼ Overall sales in NGS: >$140 m QIAseq Tumor Mutational Burden Panel ◼ Universal NGS portfolio Assay solutions based on proprietary Digital NGS technology – Target enrichment – Library prepar
Slide 11: Molecular Diagnostics customer class
Portfolio strength Molecular Diagnostics customer class ~$4-5 billion addressable market ◼ 12-month run rate of ~$750 million (as of Q3 2018) ◼ Focus on high-growth, high-demand opportunities Molecular ~6-7% CER market growth ◼ Significant automation portfolio expansion in 2018 Diagnostics ◼ Multi-y
Slide 12: Addressing majority of ~$4.8 billion 2018 Molecular Diagnostics market opportunity
Portfolio strength Addressing majority of ~$4.8 billion 2018 Molecular Diagnostics market opportunity Single-plex PON Arrays Benchtop NGS ◼ GeneReader NGS System Real-time PCR Syndromic testing Fully integrated sample ◼ QIAstat-Dx and assay technologies ◼ NeuMoDx 96 and 288 Real-time PCR Modular sam
Slide 13: Next-generation system for syndromic testing: QIAstat-Dx
Portfolio strength Case study: Next-generation system for syndromic testing QIAstat-Dx ◼ Addressing a ~$800 million market opportunity ◼ EU launch in mid-2018 after STAT-Dx acquisition(1) ◼ Plan for mid-2019 U.S. launch (FDA submission completed) ◼ Differentiation: Ease of use, PCR-based system and
Slide 14: Disruptive PCR technology for integrated testing: NeuMoDx
Portfolio strength Case study: Disruptive PCR technology for integrated testing NeuMoDx 96 / 288 ◼ Entering ~$2.7 billion market ◼ Synergistic with QIAGEN’s strong positioning in this lab testing segment ◼ 2018 EU launch, complements QIAsymphony (modular segment) ◼ Differentiation: Speed, full rando
Slide 15: Complete NGS solution for actionable results: GeneReader NGS System
Portfolio strength Case study: Complete NGS solution for actionable results GeneReader NGS System ◼ Gaining share in ~$300m global benchtop oncology NGS market ◼ Offering full menu for cancer gene panels ◼ Strong sales channels in molecular pathology labs ◼ Integrating with PCR, syndromic and QFT ap
Slide 16: Significant assay menu expansion under way to address large market opportunities
Portfolio strength Selected assay roadmap (2018-2021) 2018 2019 2020 2021 Respiratory Respiratory Meningitis Positive Blood Culture Gastrointestinal Gastrointestinal Oncology Pneumonia QIAstat-Dx Meningitis Positive Blood Culture CLIA Waiver Respiratory Pneumonia GBS GBS CMV FluA&B/RSV CMV CT/NG GAS
Slide 17: Novel technology for latent TB testing: QuantiFERON-TB Access
Portfolio strength Case study: Novel technology for latent TB testing QuantiFERON-TB Access (QFT Access) ◼ QFT Access: Modern TB test for low-resource, high-burden regions No continuous power No calibration or supply needed maintenance needed 85% of TB cases in top 30 high-burden countries No comp
Slide 18: Boosting clinical NGS interpretation: N-of-One clinical interpretation services
Portfolio strength Case study: Boosting clinical NGS interpretation N-of-One clinical interpretation services ◼ Acquisition of N-of-One (privately-held U.S. company) QCI Interpret Software Platform Pioneer in molecular oncology decision support services ◼ Analysis QIAGEN ◼ Well recognized services
Slide 19: Operational efficiency: track record of delivering targets
Operational efficiency Key efficiency initiatives Key outcomes Sales channel ◼ Significant change in “go-to-market” strategy efficiencies ◼ Shifting customers to digital channels ◼ Created disruptive platform portfolio Portfolio optimization ◼ Implemented China growth strategy ◼ Divested veterinary
Slide 20: Capital allocation: ongoing commitment to increasing returns
Capital allocation Reinvest for organic growth Leverage ratio ◼ Expansion of differentiated, highly focused portfolio ◼ Efficiency improvements, digitization 3.3 Disciplined Increase returns 2.2 capital ◼ $100 million done of current $200 million commitment 1.6 1.5 1.6 allocation ◼ Reviewing options
Slide 21: We are on track to achieve our 2020 ambitions
2020 ambitions Net sales Adjusted EPS Operating cash flow ~+7-9% CER ≥12% CER CAGR CAGR ~$600 m $1,338 m +6% CER $1.11 $340 m 2016 2020 2016 2020 2016 2020 target target target We are on track to achieve our 2020 ambitions Sample to Insight Kepler Cheuvreux German Corporate Conference, January 2019
Slide 22: Looking ahead to 2019
Looking ahead to 2019: Delivering on growth opportunities from a dynamic and disruptive portfolio of Sample to Insight solutions Sample to Insight Kepler Cheuvreux German Corporate Conference, January 2019 22
Qiagen — Kepler Cheuvreux 18th German Corporate Conference, January 2019 on 6ix